Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rmhTNF vs paclitaxel intraperitoneal perfusion for peritoneal metastasis of gastric cancer
ChiCTR2400083006Phase 4Recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Apr 2024
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of tasonermin and paclitaxel in gastric cancer (GC) (3 arms), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: 1-year overall survival rate. Started Apr 2024; status: recruiting.
02
Drugs
tasonerminpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2400083006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083006.